Why Medicaid Cuts Are Leaving Millions Without Access to GLP‑1 Weight‑Loss Meds

When Dr. Ian Huntington first started prescribing GLP‑1 medications at Codman Square Community Health Center in Boston, he watched his patients drop pounds, walk farther, and smile a little more. The drugs—originally designed for diabetes, but now celebrated for dramatic weight loss—were a lifeline for many who’d struggled for years.

Then, on July 1, Massachusetts Medicaid pulled the plug on the weight‑loss indication. Suddenly, a medication that cost between $150 and $450 a month had to be paid for out of pocket. For the clinic’s low‑income patients, that was an impossible ask.

“In some ways, offering the medication for a period of time and then taking it away has actually left some patients worse off than if they had never gotten it,” Dr. Huntington said, sounding both frustrated and exhausted.

Massachusetts isn’t alone. Michigan trimmed its coverage to only the most severely obese, Rhode Island will stop paying for the drugs altogether in October, and states like California, New Hampshire, Pennsylvania and South Carolina have already tightened their policies. A Washington Post review shows that while about a third of states covered GLP‑1s for weight loss in mid‑2025, that figure has slipped to roughly one‑fifth this year.

The numbers sound abstract until you hear from people like Traci Seifert, a 44‑year‑old Utah Medicaid enrollee. After losing her job, she qualified for the state’s tiny pilot program, only to be denied Zepbound because she didn’t meet the new, stricter BMI thresholds. “Your whole life you hear you’re too fat, and now you’re not fat enough,” she muttered, eyes weary. She’s now resorting to cheap, compounded versions sold online—products the FDA warns are unregulated.

Doctors warn that the abrupt cessation of therapy can trigger a “metabolic yo‑yo” effect: weight rebounds, often with a higher fat‑to‑muscle ratio than before. The health fallout isn’t just a number on the scale; patients risk higher blood pressure, rising cholesterol, joint pain and chronic inflammation—all the things the drugs helped keep in check.

State officials argue that the $2.8 billion bill—most of it driven by California’s hefty enrollment—has become untenable. Yet the burden falls hardest on those who need the medication most. “People with lower incomes, now that you’re dropping coverage, those are the patients who are going to suffer the most,” says New Hampshire obesity specialist Joseph Zucchi.

Even where coverage remains, it’s patchy. Utah’s pilot touches just 120 people. Michigan’s policy caps treatment at a BMI of 40 or higher, leaving many who sit in the 35‑39 range—still at high risk—out in the cold.

All told, the retreat is reshaping the obesity landscape into a stark divide between the “haves” who can afford private prescriptions and the “have‑nots” who now watch their progress melt away. The public‑health stakes are high, and the conversation about cost versus care is only getting louder.